16 research outputs found
Treatment outcome and the genetic characteristics of acute promyelocytic leukemia in children in Poland from 2005 to 2018
High frequency of fusion gene transcript resulting from t(10;11)(p12;q23) translocation in pediatric acute myeloid leukemia in Poland
Retrospective analysis of the treatment outcome in myeloid leukemia of down syndrome in Polish pediatric leukemia and lymphoma study group from 2005 to 2019
Profile of infections in Polish pediatric hematology, oncology and stem cell transplantation centers in 2014-2015
Epidemiological analysis of staphylococci infections in patients treated for malignancy or undergoing stem cell transplant : update report 2016
Isolated central nervous system relapses in patients with high-risk neuroblastoma - clinical presentation and prognosis : experience of the Polish Paediatric Solid Tumours Study Group
Although isolated central nervous system (CNS) relapses are rare, they may become a serious clinical problem in intensively treated patients with high-risk neuroblastoma (NBL). The aim of this study is the presentation and assessment of the incidence and clinical course of isolated CNS relapses. Retrospective analysis involved 848 NBL patients treated from 2001 to 2019 at 8 centres of the Polish Paediatric Solid Tumours Study Group (PPSTSG). Group characteristics at diagnosis, treatment and patterns of relapse were analysed. Observation was completed in December 2020. We analysed 286 high risk patients, including 16 infants. Isolated CNS relapse, defined as the presence of a tumour in brain parenchyma or leptomeningeal involvement, was found in 13 patients (4.5%; 8.4% of all relapses), all of whom were stage 4 at diagnosis. Isolated CNS relapses seem to be more common in young patients with stage 4 MYCN amplified NBL, and in this group they may occur early during first line therapy. The only or the first symptom may be bleeding into the CNS, especially in younger children, even without a clear relapse picture on imaging, or the relapse may be clinically asymptomatic and found during routine screening. Although the incidence of isolated CNS relapses is not statistically significantly higher in patients after immunotherapy, their occurrence should be carefully monitored, especially in intensively treated infants, with potential disruption of the brain-blood barrier